Navigation Links
Tris Pharma Appoints Vice President of Human Resources
Date:6/29/2011

MONMOUTH JUNCTION, N.J., June 29, 2011 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, has appointed Ms. Cheryl Patnick to the position of Vice President of Human Resources. Ms. Patnick had been working with Tris as a consultant for about a year, and will now lead and manage Tris' human resource activities as an executive of the company.

"Tris is at a point in its evolution where it needs leaders who are willing to take charge of the increasing demands of a rapidly growing company while concurrently supporting the culture that has led to its growth.  Cheryl who has been working with me for more than a year is one such leader. We are fortunate to have her joining us in this strategically important position," said Ketan Mehta, President and CEO of Tris Pharma.

With over 20 years of Human Resources and Merger/Acquisition experience, Cheryl is highly experienced in ensuring workforce maintains a high-level of productivity during times of change and accelerated growth. Most recently, Cheryl served as President of Capella Consultants LLC, where she led the Human Resources and Management consulting group.  Prior to Capella, Cheryl spent more than 15 years at Sovereign Bank, the last seven years as Executive Vice President, Human Resources.  She is active in the central New Jersey business community as a volunteer and was a recipient of the HR Person of the Year award from the Society of Human Resources Management. She earned a Bachelor of Science in Business Administration, summa cum laude, from the University of Richmond, Virginia.

"I have been working with Ketan and his team at Tris for over one year and admire the team's leadership, integrity and work ethic.  It is truly an environment where individual talent is recognized and aligned with innovation and quality," said Cheryl Patnick.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacy Choice and Access Now Coalition Applauds Passage of Senate Bill 7 During Texas Legislatures Special Session
2. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
3. Tibotec Pharmaceuticals Announces Agreement With Gilead Sciences to Develop and Commercialize a New Fixed-Dose Combination of PREZISTA® and Cobicistat
4. PharmaNets Bioanalytical Laboratory Recognized by the Standards Council of Canada for Good Laboratory Practice Compliance
5. Recently Launched Pharmacy Xpressdelivery.Com Offers Fair Deals on Popular Drugs
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
8. Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain
9. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
10. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
11. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... AMSTERDAM , April 20, 2017  AbbVie ... that 99 percent (n=145/146) of chronic hepatitis C ... 4, 5 or 6 and compensated cirrhosis (Child-Pugh ... post-treatment (SVR 12 ) with its investigational, pan-genotypic ... rates were seen following 12 weeks of ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new ... is not known to have significant interactions with antiretroviral therapy (ART). Among ... levels and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. ... has not found any of them to be very practical. She wanted to write ... easily make changes in their health. It prompted her in writing “ A Clear ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical stage ... the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna ... advances towards regulatory and clinical phases. , "This is another important step for ...
(Date:4/22/2017)... Carolina (PRWEB) , ... April 22, 2017 , ... Ecommerce ... the United States estimated to be $394.9 billion. The consequences of rapid innovation ... inevitably demolishes) the limits of technology, it is every business and individual’s job to ...
Breaking Medicine News(10 mins):